Key Developments: Bioporto A/S (BIOPOR.CO)

BIOPOR.CO on Copenhagen Stock Exchange

30 Mar 2015
Change (% chg)

kr.-0.04 (-2.34%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

BioPorto A/S announces guidance for FY 2015
Wednesday, 18 Mar 2015 03:51am EDT 

BioPorto A/S:Expects positive developments to continue in FY 2015, when revenue is expected to grow by 15-35 pct, while operating loss will be further reduced.Revenue growth is expected to lead to an annual loss of 8 million-10 million crowns.FY 2015 operational result (EBIT) is realized with an expected loss of 10 million – 12 million crowns.  Full Article

BioPorto appoints Birgitte Svendsen interim CFO
Tuesday, 6 Jan 2015 03:10am EST 

BioPorto A/S:Otto Rasmussen will step down as CFO of Bioporto at Jan. 31, 2015 to become finance director of Xellia Pharmaceuticals, a company owned by Novo A/S.Says Birgitte Svendsen has been appointed interim CFO of Bioporto from Feb. 1, 2015.  Full Article

BioPorto narrows FY 2014 profit after taxes guidance
Friday, 7 Nov 2014 02:24am EST 

BioPorto A/S:Says as expectations for FY 2014 net profit after taxes is narrowed from a loss of 10-14 million crowns to a loss of around 14 million crowns.  Full Article

BioPorto maintains FY 2014 outlook
Friday, 8 Aug 2014 02:00am EDT 

BioPorto A/S:Maintains FY 2014 expectations.Sees FY 2014 revenue of around 19-23 million Danish crowns, equivalent to a growth rate of 15-40 pct.  Full Article

BioPorto elects PWC as auditor
Thursday, 10 Apr 2014 05:48am EDT 

BioPorto A/S:Elects PWC as auditor for the company.  Full Article

EPO rules BioPorto NGAL cutoff-patent invalid
Tuesday, 1 Apr 2014 08:51am EDT 

BioPorto A/S:Says the European Patent Office (EPO) has decided that the company's NGAL cutoff patent no. EP1831699 does not meet the requirements for adequate description.Says the patent is thus ruled invalid.  Full Article

BioPorto issues FY 2014 guidance
Wednesday, 19 Mar 2014 12:23pm EDT 

BioPorto A/S:Expects to generate revenue of between 19 million Danish crowns and 23 million Danish crowns in 2014, equivalent to a growth rate of 15–40 percent in the fiscal year 2014.Expects a loss of between 10 million Danish crowns and 14 million Danish crowns in the fiscal year 2014.  Full Article

BioPorto announces settlement between the company and Phadia in patent case
Saturday, 1 Mar 2014 04:03am EST 

BioPorto A/S:Says the company and Phadia have reached a settlement in the case regarding the revocation of Phadia’s patent DK/EP 0756 708, which cites the use of HNL (another designation of NGAL) as a diagnostic marker of human illness.Along with the settlement, the company receives a worldwide license to Phadia’s patents in the NGAL area and achieves free market access for its portfolio of NGAL products.  Full Article

BioPorto enters intellectual property license agreement with Abbott
Saturday, 1 Mar 2014 03:49am EST 

BioPorto A/S:Enters agreement with Abbott to cross-license their respective NGAL intellectual property rights (IPR).The agreements are non-exclusive and cover all the NGAL related IPR directly and indirectly controlled by both parties – including sub-licenses from Phadia and Cincinnati Children’s Hospital.Terms of the agreements include upfront fees and royalties paid on sales for both parties.  Full Article

BioPorto A/S receives intention to grant for NGAL exclusion patent in Europe
Friday, 21 Feb 2014 02:50am EST 

BioPorto A/S:Says the European Patent Office has published intention to grant BioPorto’s patent no. EP2064553 regarding exclusion of acute kidney injury.Says the patent is part of BioPorto’s IP rights in the NGAL area and is complementary to the NGAL cutoff patent.  Full Article

BRIEF-Bioporto FY EBIT loss narrows to DKK 15.3 million

* FY revenue 18.7 million Danish crowns ($2.66 million) versus 16.6 million crowns year ago

No consensus analysis data available.
Search Stocks